FDA

Nov 22, 2018

Cambrex takes over Avista in USD 250 Million agreement Cambrex, life sciences company, is taking over Avista Pharma Solutions with a deal of USD 250 million to become a leading contract development and manufacturing organization (CDMO). The agreement includes the early-stage drug development and manufacturing capabi...

Nov 20, 2018

Gene editing, a possible treatment, for inherited kidney disease Joubert syndrome, an inherited brain disorder that causes kidney failure in patients. This requires a transplant or dialysis. A mutation in the gene CEP290 causes the inherited form of kidney disease and scientists in the U.K. to apprise of having an e...

Nov 06, 2018

FDA approves Zulresso of Sage Sage Therapeutics, a clinical-stage biopharmaceutical company committed to the treatment of central nervous system (CNS) disorders, receives U.S. approval for its postpartum depression (PPD) drug Zulresso from the Food and Drug Administration when received 17-1 in favour of the therapy...

Oct 30, 2018

TherapeuticsMD bags FDA approval for hormone therapy The FDA has nodded hormone therapy of TherapeuticsMD for hot flashes that are associated with menopause. Bijuva is an oral treatment that contains molecularly identical (bio-identical) versions of the hormones estradiol and progesterone for menopausal women with a...

Oct 29, 2018

Oral Mucositis (OM) refers to erythematous and ulcerative lesions of the oral mucosa observed in cancer patients under chemotherapy or radiation therapy. In its severe form, OM presents as confluent, deep ulcerations. Typical manifestations are atrophy, erythema, ulceration, and swelling of the mucosa. It appears fi...

Oct 11, 2018

Cytosen Therapeutics and KBI Biopharma pair up to manufacture NK cells and Nanoparticles  CytoSen Therapeutics and KBI Biopharma paired up to manufacture therapeutic Natural Killer Cell by using a closed system manufacturing process. According to the initial collaboration, KBI will be subjected to manufactur...

Oct 09, 2018

FDA approves transthyretin amyloidosis therapy of Akcea, Ionis Patients with an orphan, hereditary disease that is transthyretin amyloidosis with a second new treatment option are available after the Food and Drug Administration approved Akcea Therapeutics and Ionis Pharmaceuticals' Tegsedi.  As Tegsedi is approved,...

Oct 03, 2018

Millions of people get bad side-effects when trying to withdraw antidepressants. The All Party Parliamentary Group for Prescribed Drug Dependence review shows half of the patients have withdrawal symptoms and for half of these, the symptoms will be severe. The patients should be properly warned for the same.The revi...

Sep 27, 2018

Ceribell raises USD 35 Million in series B round Ceribell, Emergency EEG maker raised USD 35 million for commercializing its EEG system that can rapidly diagnose patients, who are supposed of not having convulsive seizures with no visual symptoms for the use in neurological intensive care units and emergency rooms. ...

Sep 25, 2018

The interleukin-33 antibody of AnaptysBio passes midstage test in asthma The pipeline drug, etokimab of AnaptysBio, has positive data in a third indication that adds asthma to one of its triumphs. The US-based company gets another proof-of-concept study for the interleukin-33 (IL-33) inhibitor, because of phase 2a ...